Correlation Between GlaxoSmithKline PLC and Innovator Russell

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both GlaxoSmithKline PLC and Innovator Russell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GlaxoSmithKline PLC and Innovator Russell into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between GlaxoSmithKline PLC ADR and Innovator Russell 2000, you can compare the effects of market volatilities on GlaxoSmithKline PLC and Innovator Russell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GlaxoSmithKline PLC with a short position of Innovator Russell. Check out your portfolio center. Please also check ongoing floating volatility patterns of GlaxoSmithKline PLC and Innovator Russell.

Diversification Opportunities for GlaxoSmithKline PLC and Innovator Russell

-0.85
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between GlaxoSmithKline and Innovator is -0.85. Overlapping area represents the amount of risk that can be diversified away by holding GlaxoSmithKline PLC ADR and Innovator Russell 2000 in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innovator Russell 2000 and GlaxoSmithKline PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GlaxoSmithKline PLC ADR are associated (or correlated) with Innovator Russell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innovator Russell 2000 has no effect on the direction of GlaxoSmithKline PLC i.e., GlaxoSmithKline PLC and Innovator Russell go up and down completely randomly.

Pair Corralation between GlaxoSmithKline PLC and Innovator Russell

Considering the 90-day investment horizon GlaxoSmithKline PLC is expected to generate 3.24 times less return on investment than Innovator Russell. In addition to that, GlaxoSmithKline PLC is 1.73 times more volatile than Innovator Russell 2000. It trades about 0.01 of its total potential returns per unit of risk. Innovator Russell 2000 is currently generating about 0.06 per unit of volatility. If you would invest  2,543  in Innovator Russell 2000 on August 30, 2024 and sell it today you would earn a total of  615.00  from holding Innovator Russell 2000 or generate 24.18% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

GlaxoSmithKline PLC ADR  vs.  Innovator Russell 2000

 Performance 
       Timeline  
GlaxoSmithKline PLC ADR 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days GlaxoSmithKline PLC ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Innovator Russell 2000 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Innovator Russell 2000 are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable fundamental indicators, Innovator Russell is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

GlaxoSmithKline PLC and Innovator Russell Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with GlaxoSmithKline PLC and Innovator Russell

The main advantage of trading using opposite GlaxoSmithKline PLC and Innovator Russell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GlaxoSmithKline PLC position performs unexpectedly, Innovator Russell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innovator Russell will offset losses from the drop in Innovator Russell's long position.
The idea behind GlaxoSmithKline PLC ADR and Innovator Russell 2000 pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Volatility Analysis
Get historical volatility and risk analysis based on latest market data
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance